Alberdi, A. (Aitor)

Filtering

20201

Settings

Author search.filters.isAuthorOfPublication.c2cd6bd9-8269-4e8f-a815-14457335c2bd

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    The urinary transcriptome as a source of biomarkers for prostate cancer
    (Cancers, 2020) Urruticoechea, A. (Ander); López, J.I. (José Ignacio); Loizaga-Iriarte, A. (Ana); Goñi, A. (Alai); Goicoechea, I. (Ibai); Roumiguie, M. (Mathieu); Sanz-Jaka, J.P. (Juan Pablo); Solé, C. (Carla); Tellaetxe, M. (Maitena); Vergara, I. (Itziar); Arestin, M. (María); Nogueira, L. (Leonor); Schramm, M. (Maike); Malavaud, B. (Bernard); Carracedo, A. (Arkaitz); Unda, M. (Miguel); Alberdi, A. (Aitor); Armesto, M. (María); Manterola, L. (Lorea); Lawrie, C.H. (Charles H.)
    Prostate cancer (PCa) is the second most common cancer of men and is typically slow-growing and asymptomatic. The use of blood PSA as a screening method has greatly improved PCa diagnosis, but high levels of false positives has raised much interest in alternative biomarkers. We used next-generation sequencing (NGS) to elucidate the urinary transcriptome of whole urine collected from high-stage and low-stage PCa patients as well as from patients with the confounding diagnosis of benign hyperplasia (BPH). We identified and validated five differentially expressed protein-coding genes (FTH1 BRPF1, OSBP, PHC3, and UACA) in an independent validation cohort of small-volume (1 mL) centrifuged urine (n = 94) and non-centrifuged urine (n = 84) by droplet digital (dd)PCR. These biomarkers were able to discriminate between BPH and PCa patients and healthy controls using either centrifuged or non-centrifuged whole urine samples, suggesting that the urinary transcriptome is a valuable source of non-invasive biomarkers for PCa that warrants further investigation.